Astrazeneca Pharma India Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8501 as of 18 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 0 on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe P/E Ratio of Sanofi Consumer Healthcare India Ltd changed from 62.6 on December 2024 to 62.6 on December 2024 . This represents a CAGR of 0.00% over 1 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 0 crore on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe Market Cap of Sanofi Consumer Healthcare India Ltd changed from ₹ 11347 crore on December 2024 to ₹ 11347 crore on December 2024 . This represents a CAGR of 0.00% over 1 years The revenue of Astrazeneca Pharma India Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 496.63 crore. This represent the decline of -100% The revenue of Sanofi Consumer Healthcare India Ltd for the Jun '26 is ₹ 234.8 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the growth of 9.2233718E16% The ebitda of Astrazeneca Pharma India Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 96.84 crore. This represent the decline of -100% The ebitda of Sanofi Consumer Healthcare India Ltd for the Jun '26 is ₹ 94.4 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the growth of 9.2233718E16% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 62.7 crore to ₹ 67.8 crore over 8 quarters. This represents a CAGR of 3.99% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 0 % on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company. Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Sanofi Consumer Healthcare India Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Sanofi Consumer Healthcare India Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,221 Cr while Market cap of Sanofi Consumer Healthcare India Ltd is 11,180 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Sanofi Consumer Healthcare India Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Sanofi Consumer Healthcare India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Sanofi Consumer Healthcare India Ltd?

As of May 18, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8488.45. On the other hand, Sanofi Consumer Healthcare India Ltd stock price is INR ₹4854.5.

How do dividend payouts of Astrazeneca Pharma India Ltd and Sanofi Consumer Healthcare India Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Sanofi Consumer Healthcare India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.